Learn Why SSDP Is Taking the DEA to Court to Protect Psychedelic Research (VIDEO)

The DEA wants to add two important research chemicals—2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC)—to Schedule I of the Controlled Substances Act, despite decades of safe usage in labs and no history of abuse.

DOI and DOC’s current status as unscheduled compounds has made them de facto tools for researchers studying serotonin receptors. They have featured in more than 900 research articles and show promise for pain management, combatting anxiety and depression, and preventing overdose.

Scheduling DOI and DOC would create serious impediments to potentially life-saving research, and yet SSDP is the only drug policy organization currently fighting to keep DOI and DOC off the Controlled Substances Act.

SSDP Science Policy Committee members Dr. Elijah Ullman, Dr. Alaina Jaster, Tanner Anderson, and Joe Hennessey discuss their own research using DOI and DOC, the considerable harm the DEA’s proposed scheduling would cause, and the role they have played in pushing back against adding DOI and DOC to the CSA.

The webinar is an opportunity for those unable to attend the courtroom proceedings to hear perspectives from leading scientists on a historic hearing that is the first of its kind since 1986.

View the webinar here.